PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma

International Journal of Cancer

Volumn 131, Issue 7, 2012, Pages 1556-1568

  Gawecka, Joanna E ^a   Geerts, Dirk ^b,c   Koster, Jan ^c   Caliva, Maisel J ^a   Sulzmaier, Florian J ^a,d   Opoku Ansah, John ^a,d   Wada, Randal K ^a   Bachmann, André S ^a,e   Ramos, Joe W ^a,d  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF HAWAII   (United States)

^e UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

migration; neuroblastoma; PEA15; RSK2

Indexed keywords

INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PEA15 PROTEIN; PHOSPHOPROTEIN; RSK2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME INHIBITION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; ONCOGENE MYCN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; CHROMOSOME ABERRATIONS; COS CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE AMPLIFICATION; HUMANS; INTEGRINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHOPROTEINS; PROGNOSIS; PROTEIN BINDING; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER;

EID: 84864459380     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27415     Document Type: Article

References (49)

1. Maris JM,. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-11.
2. Brodeur GM,. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
3. Park JR, Eggert A, Caron H,. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 2008; 55: 97-120.
4. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, Matthay KK,. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92: 2451-61.
5. Joshi VV,. Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatr Dev Pathol 2000; 3: 184-99.
6. Ara T, DeClerck YA,. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev 2006; 25: 645-57.
7. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-97.
8. De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27: 1034-40.
9. Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, Ladenstein R, Brichard B, Bermudez JD, Couturier J, de Bernardi B, Pearson AJ, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009; 27: 1014-19.
10. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009; 100: 1471-82.
11. Araujo H, Danziger N, Cordier J, Glowinski J, Chneiweiss H,. Characterization of PEA-15, a major substrate for protein kinase C in astrocytes. J Biol Chem 1993; 268: 5911-20.
12. Danziger N, Yokoyama M, Jay T, Cordier J, Glowinski J, Chneiweiss H,. Cellular expression, developmental regulation, and phylogenic conservation of PEA-15, the astrocytic major phosphoprotein and protein kinase C substrate. J Neurochem 1995; 64: 1016-25.
13. Fiory F, Formisano P, Perruolo G, Beguinot F,. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am J Physiol Endocrinol Metab 2009; 297: E592-E601.
14. Ramos JW, Kojima TK, Hughes PE, Fenczik CA, Ginsberg MH,. The death effector domain of PEA-15 is involved in its regulation of integrin activation. J Biol Chem 1998; 273: 33897-900.
15. Ramos JW, Hughes PE, Renshaw MW, Schwartz MA, Formstecher E, Chneiweiss H, Ginsberg MH,. Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion-independent mechanism. Mol Biol Cell 2000; 11: 2863-72.
16. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, et al. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 2010; 16: 1802-11.
17. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT,. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 2008; 68: 9302-10.
18. Condorelli G, Vigliotta G, Iavarone C, Caruso M, Tocchetti CG, Andreozzi F, Cafieri A, Tecce MF, Formisano P, Beguinot L, Beguinot F,. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J 1998; 17: 3858-66.
19. Condorelli G, Vigliotta G, Cafieri A, Trencia A, Andalo P, Oriente F, Miele C, Caruso M, Formisano P, Beguinot F,. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999; 18: 4409-15.
20. Glading A, Koziol JA, Krueger J, Ginsberg MH,. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007; 67: 1536-44.
21. Renault F, Formstecher E, Callebaut I, Junier MP, Chneiweiss H,. The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochem Pharmacol 2003; 66: 1581-88.
22. Renault-Mihara F, Beuvon F, Iturrioz X, Canton B, De BS, Leonard N, Mouhamad S, Sharif A, Ramos JW, Junier MP, Chneiweiss H,. Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism. Mol Biol Cell 2006; 17: 5141-52.
23. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT,. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 2006; 25: 79-90.
24. Formisano P, Perruolo G, Libertini S, Santopietro S, Troncone G, Raciti GA, Oriente F, Portella G, Miele C, Beguinot F,. Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development. Oncogene 2005; 24: 7012-21.
25. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C,. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002; 277: 25020-25.
26. Chou FL, Hill JM, Hsieh JC, Pouyssegur J, Brunet A, Glading A, Uberall F, Ramos JW, Werner MH, Ginsberg MH,. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J Biol Chem 2003; 278: 52587-97.
27. Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B, Nguyen XT, Barnier JV, Camonis J, Ginsberg MH, Chneiweiss H,. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev Cell 2001; 1: 239-50.
28. Vaidyanathan H, Ramos JW,. RSK2 activity is regulated by its interaction with PEA-15. J Biol Chem 2003; 278: 32367-72.
29. Vaidyanathan H, Opoku-Ansah J, Pastorino S, Renganathan H, Matter ML, Ramos JW,. ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15. Proc Natl Acad Sci USA 2007; 104: 19837-42.
30. Smith JA, Poteet-Smith CE, Malarkey K, Sturgill TW,. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J Biol Chem 1999; 274: 2893-98.
31. Cohen MS, Zhang C, Shokat KM, Taunton J,. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 2005; 308: 1318-21.
32. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA,. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005; 65: 1027-34.
33. Cheng NC, Van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, Versteeg R,. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene 1995; 10: 291-7.
34. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M,. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13: 803-12.
35. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM,. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006; 3: 715-19.
36. Hill JM, Vaidyanathan H, Ramos JW, Ginsberg MH, Werner MH,. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. EMBO J 2002; 21: 6494-504.
37. Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Ora I, Versteeg R, Geerts D,. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 2008; 314: 707-19.
38. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 2009; 37: D885-D890.
39. Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS,. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010; 126: 2012-24.
40. Huttenlocher A, Ginsberg MH, Horwitz AF,. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 1996; 134: 1551-62.
41. Kang S, Elf S, Lythgoe K, Hitosugi T, Taunton J, Zhou W, Xiong L, Wang D, Muller S, Fan S, Sun SY, Marcus AI, et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest 2010; 120: 1165-77.
42. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR, Winther O, Taunton J, et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 2009; 35: 511-22.
43. Castleberry RP,. Neuroblastoma. Eur J Cancer 1997; 33: 1430-7; discussion 37-8.
44. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77.
45. Geerts D, Wallick CJ, Koomoa DL, Koster J, Versteeg R, Go RC, Bachmann AS,. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clin Cancer Res 2007; 13: 6312-19.
46. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res 1994; 385: 363-9.
47. Bown N,. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 2001; 54: 897-910.
48. O'Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak MK, Sedivy JM,. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003; 278: 12563-73.
49. Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA,. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010; 293: 144-57.